Skip to main content
SpringerLink
Log in

Supportive Care for Amyloidosis

  • Chapter
  • First Online:
Amyloidosis

Part of the book series: Contemporary Hematology ((CH))

Abstract

Supportive measures for the care of amyloid patients are reviewed here. Cardiac issues include medical management of congestive heart failure and arrhythmias including the use of defibrillators and the use of pleural catheters for diuretic-refractory effusions. The indications for solid organ transplant are reviewed including heart transplant for AL and non-AL amyloid, liver transplant for ATTR and non-ATTR familial amyloid, and kidney transplant for AL, AA, and AFib. Medical management of renal issues including agents to reduce proteinuria and the use of eprodisate to slow progression of AA amyloid is discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Rubinow A, Skinner M, Cohen AS. Digoxin sensitivity in amyloid cardiomyopathy. Circulation 1981;63:1285–8.

    Article  PubMed  CAS  Google Scholar 

  2. Gertz MA, Skinner M, Connors LH, Falk RH, Cohen AS, Kyle RA. Selective binding of nifedipine to amyloid fibrils. Am J Cardiol. 1985;55:1646.

    Article  PubMed  CAS  Google Scholar 

  3. Pollak A, Falk RH. Left ventricular systolic dysfunction precipitated by verapamil in cardiac amyloidosis. Chest 1993;104:618–20.

    Article  PubMed  CAS  Google Scholar 

  4. Gertz MA, Falk RH, Skinner M, Cohen AS, Kyle RA. Worsening of congestive heart failure in amyloid heart disease treated by calcium channel-blocking agents. Am J Cardiol. 1985;55:1645.

    Article  PubMed  CAS  Google Scholar 

  5. Austin BA, Duffy B, Tan C, Rodriguez ER, Starling RC, Desai MY. Comparison of functional status, electrocardiographic, and echocardiographic parameters to mortality in endomyocardial-biopsy proven cardiac amyloidosis. Am J Cardiol. 2009;103:1429–33.

    Article  PubMed  Google Scholar 

  6. Herlihy JP, Loyalka P, Gnananandh J, Gregoric ID, Dahlberg CG, Kar B, Delgado RM 3rd. PleurX catheter for the management of refractory pleural effusions in congestive heart failure. Tex Heart Inst J. 2009;36:38–43.

    PubMed  Google Scholar 

  7. Hoyer RJ, Leung N, Witzig TE, Lacy MQ. Treatment of diuretic refractory pleural effusions with bevacizumab in four patients with primary systemic amyloidosis. Am J Hematol. 2007;82:409–13.

    Article  PubMed  Google Scholar 

  8. Pichelmayer O, Zielinski C, Raderer M. Response of a nonmalignant pleural effusion to bevacizumab. N Engl J Med. 2005;353:740–1.

    Article  PubMed  CAS  Google Scholar 

  9. Kimlinger T, Kline M, Kumar S, Lust J, Witzig T, Rajkumar SV. Differential expression of vascular endothelial growth factors and their receptors in multiple myeloma. Haematologica 2006;91:1033–40.

    PubMed  CAS  Google Scholar 

  10. Rajkumar SV, Kyle RA. Angiogenesis in multiple myeloma. Semin Oncol. 2001;28:560–4.

    Article  PubMed  CAS  Google Scholar 

  11. Shulman K, Rosen S, Tognazzi K, Manseau EJ, Brown LF. Expression of vascular permeability factor (VPF/VEGF) is altered in many glomerular diseases. J Am Soc Nephrol. 1996;7:661–6.

    PubMed  CAS  Google Scholar 

  12. Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol. 1995;32:45–59.

    PubMed  CAS  Google Scholar 

  13. Dubrey SW, Cha K, Skinner M, LaValley M, Falk RH. Familial and primary (AL) cardiac amyloidosis: echocardiographically similar diseases with distinctly different clinical outcomes. Heart 1997;78:74–82.

    PubMed  CAS  Google Scholar 

  14. Conner R, Hosenpud JD, Norman DJ, Pantely GA, Cobanoglu A, Starr A. Heart transplantation for cardiac amyloidosis: successful one-year outcome despite recurrence of the disease. J Heart Transplant. 1988;7:165–7.

    PubMed  CAS  Google Scholar 

  15. Hosenpud JD, DeMarco T, Frazier OH, Griffith BP, Uretsky BF, Menkis AH, O’Connell JB, Olivari MT, Valantine HA. Progression of systemic disease and reduced long-term survival in patients with cardiac amyloidosis undergoing heart transplantation. Follow-up results of a multicenter survey. Circulation 1991;84:III338–43.

    PubMed  CAS  Google Scholar 

  16. Hosenpud JD, Uretsky BF, Griffith BP, O’Connell JB, Olivari MT, Valantine HA. Successful intermediate-term outcome for patients with cardiac amyloidosis undergoing heart transplantation: results of a multicenter survey. J Heart Transplant. 1990;9:346–50.

    PubMed  CAS  Google Scholar 

  17. Dubrey SW, Burke MM, Khaghani A, Hawkins PN, Yacoub MH, Banner NR. Long term results of heart transplantation in patients with amyloid heart disease 10.1136/heart.85.2.202. Heart 2001;85:202–7.

    Article  PubMed  CAS  Google Scholar 

  18. Dubrey SW, Burke MM, Hawkins PN, Banner NR. Cardiac transplantation for amyloid heart disease: the United Kingdom experience. J Heart Lung Transplant. 2004;23:1142–53.

    Article  PubMed  Google Scholar 

  19. Kpodonu J, Massad MG, Caines A, Geha AS. Outcome of heart transplantation in patients with amyloid cardiomyopathy. J Heart Lung Transplant. 2005;24:1763–5.

    Article  PubMed  Google Scholar 

  20. Gillmore JD, Goodman HJ, Lachmann HJ, Offer M, Wechalekar AD, Joshi J, Pepys MB, Hawkins PN. Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis. Blood 2006;107:1227–9.

    Article  PubMed  CAS  Google Scholar 

  21. Sack FU, Kristen A, Goldschmidt H, Schnabel PA, Dengler T, Koch A, Karck M. Treatment options for severe cardiac amyloidosis: heart transplantation combined with chemotherapy and stem cell transplantation for patients with AL-amyloidosis and heart and liver transplantation for patients with ATTR-amyloidosis. Eur J Cardiothorac Surg. 2008;33:257–62.

    Article  PubMed  Google Scholar 

  22. Perz JB, Kristen AV, Rahemtulla A, Parameshwar J, Sack FU, Apperley JF, Goldschmidt H, Katus HA, Dengler TJ. Long-term survival in a patient with AL amyloidosis after cardiac transplantation followed by autologous stem cell transplantation. Clin Res Cardiol. 2006;95:671–4.

    Article  PubMed  CAS  Google Scholar 

  23. Maurer MS, Raina A, Hesdorffer C, Bijou R, Colombo P, Deng M, Drusin R, Haythe J, Horn E, Lee SH, Marboe C, Naka Y, Schulman L, Scully B, Shapiro P, Prager K, Radhakrishnan J, Restaino S, Mancini D. Cardiac transplantation using extended-donor criteria organs for systemic amyloidosis complicated by heart failure. Transplantation 2007;83:539–45.

    Article  PubMed  Google Scholar 

  24. Lacy MQ, Dispenzieri A, Hayman SR, Kumar S, Kyle RA, Rajkumar SV, Edwards BS, Rodeheffer RJ, Frantz RP, Kushwaha SS, Clavell AL, Dearani JA, Sundt TM, Daly RC, McGregor CG, Gastineau DA, Litzow MR, Gertz MA. Autologous stem cell transplant after heart transplant for light chain (Al) amyloid cardiomyopathy. J Heart Lung Transplant. 2008;27:823–9.

    Article  PubMed  Google Scholar 

  25. Mignot A, Varnous S, Redonnet M, Jaccard A, Epailly E, Vermes E, Boissonnat P, Gandjbakhch I, Herpin D, Touchard G, Bridoux F. Heart transplantation in systemic (AL) amyloidosis: a retrospective study of eight French patients. Arch Cardiovasc Dis. 2008;101:523–32.

    Article  PubMed  Google Scholar 

  26. Mignot A, Bridoux F, Thierry A, Varnous S, Pujo M, Delcourt A, Gombert JM, Goujon JM, Favreau F, Touchard G, Herpin D, Jaccard A. Successful heart transplantation following melphalan plus dexamethasone therapy in systemic AL amyloidosis. Haematologica 2008;93:e32–5.

    Article  PubMed  Google Scholar 

  27. Grazi GL, Cescon M, Salvi F, Ercolani G, Ravaioli M, Arpesella G, Magelli C, Grigioni F, Cavallari A. Combined heart and liver transplantation for familial amyloidotic neuropathy: considerations from the hepatic point of view. Liver Transpl. 2003;9:986–92.

    Article  PubMed  Google Scholar 

  28. Dubrey SW, Davidoff R, Skinner M, Bergethon P, Lewis D, Falk RH. Progression of ventricular wall thickening after liver transplantation for familial amyloidosis. Transplantation 1997;64:74–80.

    Article  PubMed  CAS  Google Scholar 

  29. Yazaki M, Mitsuhashi S, Tokuda T, Kametani F, Takei YI, Koyama J, Kawamorita A, Kanno H, Ikeda SI. Progressive wild-type transthyretin deposition after liver transplantation preferentially occurs onto myocardium in FAP patients. Am J Transplant. 2007;7:235–42.

    Article  PubMed  CAS  Google Scholar 

  30. Holmgren G, Steen L, Ekstedt J, Groth CG, Ericzon BG, Eriksson S, Andersen O, Karlberg I, Norden G, Nakazato M, et al. Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30). Clin Genet. 1991;40:242–6.

    Article  PubMed  CAS  Google Scholar 

  31. Herlenius G, Wilczek HE, Larsson M, Ericzon BG. Ten years of international experience with liver transplantation for familial amyloidotic polyneuropathy: results from the Familial Amyloidotic Polyneuropathy World Transplant Registry. Transplantation 2004;77:64–71.

    Article  PubMed  Google Scholar 

  32. Ericzon BG, Larsson M, Wilczek HE. Domino liver transplantation: risks and benefits. Transplant Proc. 2008;40:1130–1.

    Article  PubMed  Google Scholar 

  33. Ericzon BG, Larsson M, Herlenius G, Wilczek HE. Report from the Familial Amyloidotic Polyneuropathy World Transplant Registry (FAPWTR) and the Domino Liver Transplant Registry (DLTR). Amyloid 2003;10 Suppl 1:67–76.

    PubMed  Google Scholar 

  34. Eriksson M, Schonland S, Yumlu S, Hegenbart U, von Hutten H, Gioeva Z, Lohse P, Buttner J, Schmidt H, Rocken C. Hereditary apolipoprotein AI-associated amyloidosis in surgical pathology specimens. Identification of three novel mutations in the APOA1 gene. J Mol Diagn. 2009;11(3):257–62.

    Article  PubMed  CAS  Google Scholar 

  35. Gillmore JD, Stangou AJ, Tennent GA, Booth DR, O’Grady J, Rela M, Heaton ND, Wall CA, Keogh JA, Hawkins PN. Clinical and biochemical outcome of hepatorenal transplantation for hereditary systemic amyloidosis associated with apolipoprotein AI Gly26Arg. Transplantation 2001;71:986–92.

    Article  PubMed  CAS  Google Scholar 

  36. Gillmore JD, Stangou AJ, Lachmann HJ, Goodman HJ, Wechalekar AD, Acheson J, Tennent GA, Bybee A, Gilbertson J, Rowczenio D, O’Grady J, Heaton ND, Pepys MB, Hawkins PN. Organ transplantation in hereditary apolipoprotein AI amyloidosis. Am J Transplant. 2006;6:2342–7.

    Article  PubMed  CAS  Google Scholar 

  37. Testro AG, Brennan SO, Macdonell RA, Hawkins PN, Angus PW. Hereditary amyloidosis with progressive peripheral neuropathy associated with apolipoprotein AI Gly26Arg: outcome of hepatorenal transplantation. Liver Transpl. 2007;13:1028–31.

    Article  PubMed  Google Scholar 

  38. Lachmann HJ, Goodman HJ, Gilbertson JA, Gallimore JR, Sabin CA, Gillmore JD, Hawkins PN. Natural history and outcome in systemic AA amyloidosis. N Engl J Med. 2007;356:2361–71.

    Article  PubMed  CAS  Google Scholar 

  39. Bergesio F, Ciciani AM, Manganaro M, Palladini G, Santostefano M, Brugnano R, Di Palma AM, Gallo M, Rosati A, Tosi PL, Salvadori M. Renal involvement in systemic amyloidosis: an Italian collaborative study on survival and renal outcome. Nephrol Dial Transplant. 2008;23:941–51.

    Article  PubMed  CAS  Google Scholar 

  40. Gertz MA, Leung N, Lacy MQ, Dispenzieri A, Zeldenrust SR, Hayman SR, Buadi FK, Dingli D, Greipp PR, Kumar SK, Lust JA, Rajkumar SV, Russell SJ, Witzig TE. Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney. Nephrol Dial Transplant. 2009 Oct;24(10):3132–7. Epub 2009 Apr 29.

    Article  PubMed  CAS  Google Scholar 

  41. Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril efficacy in nephropathy. Lancet 1998;352:1252–6.

    Article  PubMed  CAS  Google Scholar 

  42. Kahvecioglu S, Dilek K, Akdag I, Gullulu M, Demircan C, Ersoy A, Yurtkuran M. Effect of indomethacin and selective cyclooxygenase-2 inhibitors on proteinuria and renal function in patients with AA type renal amyloidosis. Nephrology (Carlton) 2006;11:232–7.

    Article  CAS  Google Scholar 

  43. Odabas AR, Cetinkaya R, Selcuk Y, Bilen H. Effect of losartan treatment on the proteinuria in normotensive patients having proteinuria due to secondary amyloidosis. Ups J Med Sci. 2001;106:183–8.

    Article  PubMed  CAS  Google Scholar 

  44. Elkayam O, Hawkins PN, Lachmann H, Yaron M, Caspi D. Rapid and complete resolution of proteinuria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infliximab. Arthritis Rheum. 2002;46:2571–3.

    Article  PubMed  Google Scholar 

  45. Serratrice J, Granel B, Disdier P, Weiller PJ, Dussol B. Resolution with etanercept of nephrotic syndrome due to renal AA amyloidosis in adult Still’s disease. Am J Med. 2003;115:589–90.

    Article  PubMed  Google Scholar 

  46. Dember LM, Hawkins PN, Hazenberg BP, Gorevic PD, Merlini G, Butrimiene I, Livneh A, Lesnyak O, Puechal X, Lachmann HJ, Obici L, Balshaw R, Garceau D, Hauck W, Skinner M. Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med. 2007;356:2349–60.

    Article  PubMed  CAS  Google Scholar 

  47. Brown JH, Maxwell AP, Bruce I, Murphy BG, Doherty CC. Renal replacement therapy in multiple myeloma and systemic amyloidosis. Ir J Med Sci. 1993;162:213–7.

    Article  PubMed  CAS  Google Scholar 

  48. Pasternack A, Ahonen J, Kuhlback B. Renal transplantation in 45 patients with amyloidosis. Transplantation. 1986;42:598–601.

    Article  PubMed  CAS  Google Scholar 

  49. Gillmore JD, Lachmann HJ, Rowczenio D, Gilbertson JA, Zeng CH, Liu ZH, Li LS, Wechalekar A, Hawkins PN. Diagnosis, pathogenesis, treatment, and prognosis of hereditary fibrinogen A alpha-chain amyloidosis. J Am Soc Nephrol. 2009;20:444–51.

    Article  PubMed  CAS  Google Scholar 

  50. Helin H, Pasternack A, Falck H, Kuhlback B. Recurrence of renal amyloid and de novo membranous glomerulonephritis after transplantation. Transplantation 1981;32:6–9.

    Article  PubMed  CAS  Google Scholar 

  51. Leung N, Griffin MD, Dispenzieri A, Haugen EN, Gloor JM, Schwab TR, Textor SC, Lacy MQ, Litzow MR, Cosio FG, Larson TS, Gertz MA, Stegall MD. Living donor kidney and autologous stem cell transplantation for primary systemic amyloidosis (AL) with predominant renal involvement. Am J Transplant. 2005;5:1660–70.

    Article  PubMed  Google Scholar 

  52. Casserly LF, Fadia A, Sanchorawala V, Seldin DC, Wright DG, Skinner M, Dember LM. High-dose intravenous melphalan with autologous stem cell transplantation in AL amyloidosis-associated end-stage renal disease. Kidney Int. 2003;63:1051–7.

    Article  PubMed  CAS  Google Scholar 

  53. Livneh A, Zemer D, Siegal B, Laor A, Sohar E, Pras M. Colchicine prevents kidney transplant amyloidosis in familial Mediterranean fever. Nephron 1992;60:418–22.

    Article  PubMed  CAS  Google Scholar 

  54. Sherif AM, Refaie AF, Sheashaa HA, El-Tantawy AE, Sobh MA. Long-term evaluation of neuromyopathy in live donor FMF amyloidotic kidney transplant recipients. Am J Nephrol. 2004;24:582–6.

    Article  PubMed  Google Scholar 

  55. Celik A, Saglam F, Dolek D, Sifil A, Soylu A, Cavdar C, Temizkan A, Bora S, Gulay H, Camsari T. Outcome of kidney transplantation for renal amyloidosis: a single-center experience. Transplant Proc. 2006;38:435–9.

    Article  PubMed  CAS  Google Scholar 

  56. Moser C, Pohl G, Haslinger I, Knapp S, Rowczenio D, Russel T, Lachmann HJ, Lang U, Kovarik J. Successful treatment of familial Mediterranean fever with Anakinra and outcome after renal transplantation. Nephrol Dial Transplant. 2009;24:676–8.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA

    Martha Q. Lacy MD

  2. Department of Nephrology and Hypertension, Mayo Clinic College of Medicine, Rochester, MN, USA

    Nelson Leung MD

Authors
  1. Martha Q. Lacy MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nelson Leung MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Mayo Clinic, First Street SW. 200, Rochester, 55905, Minnesota, USA

    Morie A. Gertz

  2. Mayo Clinic, First Street SW. 200, Rochester, 55905, Minnesota, USA

    S. Vincent Rajkumar

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Lacy, M.Q., Leung, N. (2010). Supportive Care for Amyloidosis. In: Gertz, M., Rajkumar, S. (eds) Amyloidosis. Contemporary Hematology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60761-631-3_5

Download citation

  • DOI: https://doi.org/10.1007/978-1-60761-631-3_5

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-60761-630-6

  • Online ISBN: 978-1-60761-631-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation